Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Trump Says Anthropic No Longer Seen as National Security Threat 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
BOSTON, Feb. 03, 2016 -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biosimilar company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs), today announced that the Company is scheduled to participate in a fireside chat at the LEERINK Partners
5th Annual Global Healthcare Conference in New York City on Wednesday, February 10, 2016 at 11:30 a.m. ET.
The link to the live audio webcast and replay of the presentation may be accessed on the EPIRUS' website at http://ir.epirusbiopharma.com/events.cfm. The webcast will be archived on the Company's website for a period of three months.
About EPIRUS Biopharmaceuticals
EPIRUS Biopharmaceuticals (Nasdaq:EPRS) is a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs). EPIRUS' goal is to improve global patient access to important, cost-effective medicines. EPIRUS' current pipeline of biosimilar product candidates includes: BOW015 (infliximab, reference biologic Remicade®); BOW050 (adalimumab, reference biologic Humira®); BOW070 (tocilizumab, reference biologic Actemra®); BOW080 (eculizumab, reference biologic Soliris®); BOW090 (ustekinumab, reference biologic STELARA®); and BOW100 (golimumab, reference biologic SIMPONI®)ii. The reference products for these candidates together generated approximately $29.2 billion in global sales for 2014, according to EvaluatePharma®. EPIRUS has established multiple partnerships to support its regulatory and commercialization efforts in global markets. For more information visit EPIRUS' website at www.epirusbiopharma.com.
Contact Information: For media inquiries: Mike Devine, FleishmanHillard +1-212-453-2324 [email protected] For investor inquiries: Marek Ciszewski, J.D. EPIRUS Biopharmaceuticals +1-617-553-9716 [email protected]
